Patients' preferences for once‐daily oral versus once‐weekly injectable diabetes medications: The REVISE study

• DOI: 10.1111/dom.14244
• Publication Date: 2020-11-03T06:46:43Z
• Authors: Kristina Boye; Melissa Ross; Reema Mody; Manige Konig; Heather Gelhorn
• Keywords: Semaglutide; Dulaglutide

Abstract Aims To understand patient preferences for once‐daily oral versus once‐weekly injectable type 2 diabetes mellitus (T2DM) medication administration profiles, and reasons their preferences. Materials methods The REVISE study, a cross‐sectional online survey of 600 participants with T2DM (United Kingdom, n = 300; United States, 300), elicited general medications, the preference. Participants then viewed two videos describing procedures dulaglutide semaglutide, based on product instructions use. Thereafter, indicated preference or video descriptions. who switched were asked to identify influencing decision. Results predominantly male (n 349; 58.2%), mean (SD) age 64 (11.3) years. Nearly all 557; 92.8%) taking an medication, 158 (26.3%) using injectable. Initially, 76.5% 459; 95% confidence interval [CI] 73.1–79.9) preferred 23.5% 141; CI 20.1–26.9; P < 0.0001). After viewing product‐specific administration, proportions preferring each option not statistically different (oral semaglutide description 315; 52.5%; 48.5–56.5; 285; 47.5%; 43.5–51.5; NS, 0.2207). most common reason switching was timing steps administration. Conclusion Several treatment‐related characteristics, including route, frequency complexity treatment, play role in patients' treatments should be considered during treatment selection.